Golimumab is actually a human monoclonal antibody administered once per month by subcutaneous injection. Despite the fact that it's got an identical basic safety and efficacy profile to other TNFi, golimumab is less efficient than other TNFi in people who have failed several biological solutions. Due to inconsistent results plus https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/